Kirkland & Ellis came out swinging this week against a lawsuit alleging that it ignored a conflict of interest by advising Teva Pharmaceutical Industries Ltd. in Teva’s ongoing $42 billion bid for rival drugmaker Mylan N.V.
On Wednesday, Kirkland filed a 46-page brief in Pittsburgh federal court opposing Mylan’s efforts to block the firm from representing Teva in the takeover battle. According to Kirkland’s outside lawyers, led by Gibson, Dunn & Crutcher’s Kevin Rosen, Mylan’s case is nothing more than a tactical ploy to thwart Teva’s unwanted M&A advances. Mylan’s May 7 preliminary injunction motion, the firm says, is “an unwarranted attack on the integrity and reputation of real people at Kirkland.”
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
